Martin Webb, MD
Nephrology · Beaufort, SCNPI 1942256516
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,800 of the $66,398 with a category attached, or 76.5%. Amgen accounts for 85.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $45,378 and has fallen 96.9% since, to $1,417 in 2025. Among nephrology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 270 payments — averaging $245.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$57K
- Calliditas Therapeutics US Inc.$6K
- Nxstage Medical, Inc.$455
- AstraZeneca$439
- Vifor Pharma, Inc.$344
- Bayer$326
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$50,80077%
- Travel & lodging$10,11615%
- Food & beverage$5,3698%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 125 | $56,836 |
| Calliditas Therapeutics US Inc. | 13 | $6,363 |
| Nxstage Medical, Inc. | 5 | $455 |
| AstraZeneca(2 entities) | 23 | $439 |
| Vifor Pharma, Inc. | 8 | $344 |
| Bayer | 13 | $326 |
| Novartis | 17 | $271 |
| Mallinckrodt Hospital Products Inc. | 9 | $189 |
| Otsuka America Pharmaceutical, Inc. | 8 | $140 |
| Aurinia Pharma U.S., Inc. | 6 | $130 |
| Travere Therapeutics, Inc. | 6 | $109 |
| E.r. Squibb & Sons, L.L.C. | 1 | $97 |
| ANI Pharmaceuticals, Inc. | 5 | $94 |
| Fresenius USA Marketing, Inc. | 5 | $93 |
| Akebia Therapeutics Inc | 4 | $89 |
| GSK | 5 | $78 |
| Daiichi Sankyo Inc. | 3 | $67 |
| Chiesi USA, Inc. | 2 | $52 |
| OPKO Pharmaceuticals, LLC | 3 | $46 |
| Sanofi | 2 | $42 |
| Corcept Therapeutics | 2 | $40 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$66,398 in reported general payments places this provider in the 95th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 20 | $46,936 |
| FarxigaDapagliflozin Propanediol | 25 | $17,680 |
| Clonidine | 12 | $633 |
| Allopurinol | 22 | $459 |
| Bumetanide | 12 | $278 |
| Losartan Potassium | 23 | $180 |
| Hydralazine Hcl | 15 | $170 |
| Amlodipine Besylate | 12 | $155 |
| Calcitriol | 17 | $142 |
| Labetalol Hcl | 11 | $101 |
| Furosemide | 23 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $93 | $46,93620 claims |
| AstraZenecaFarxiga | $439 | $17,68025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Beaufort
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Mohammed AlzubaidiSumter$54K
- Joshua LipschutzCharleston$44K
- Renee EllisColumbia$40K
- Charles BunkeCharleston$39K
- Anand AchantiCharleston$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.